Axsome Therapeutics 2024年第四季度GAAP每股收益$(1.54) 未达$(1.03)预期,销售额$1.1877亿超出$1.1764亿预期

财报速递2025-02-18
Axsome Therapeutics (NASDAQ:AXSM)报告季度每股亏损$(1.54),未达到分析师普遍预期的$(1.03),差距为49.51%。相比去年同期每股亏损$(2.08),这是一个25.96%的改善。公司报告季度销售额为$1.1877亿,超出分析师普遍预期的$1.1764亿,超出幅度为0.95%。相比去年同期的$7153万,销售额增长了66.03%。

以上内容来自Benzinga Earnings专栏,原文如下:

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.54) per share which missed the analyst consensus estimate of $(1.03) by 49.51 percent. This is a 25.96 percent increase over losses of $(2.08) per share from the same period last year. The company reported quarterly sales of $118.77 million which beat the analyst consensus estimate of $117.64 million by 0.95 percent. This is a 66.03 percent increase over sales of $71.53 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法